Icon
+91 94997 68112
Login Register

Breo Ellipta - (0.1MG;0.025MG, 0.2MG;0.025MG, 0.05MG;0.025MG)

Fluticasone furoate None
0.1MG;0.025MG, 0.2MG;0.025MG, 0.05MG;0.025MG
Less Than $1000 mn
None None
None None
None None
BREO ELLIPTA is a combination of fluticasone furoate, an inhaled corticosteroid (ICS), and vilanterol, a long-acting beta2-adrenergic agonist (LABA), indicated for: • Long-term, once-daily, maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). • Once-daily treatment of asthma in patients aged 18 years and older.
Yes
Breo Ellipta Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16 Patent 17
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.